To
elevate the accurate diagnosis of tumors, nanomaterial-based
magnetic resonance imaging (MRI) contrast agents are being rapidly
developed. In this paper, we report the large-scale synthetic method
of Fe3O4 nanoparticles by high-temperature thermal
decomposition and their application as time-dependent T
1–T
2 dual-modal MRI
contrast agents in rabbit hepatic tumors. The Fe3O4 nanoparticles are modified with bull serum albumin (BSA),
which provides excellent biocompatibility and colloidal stability.
These nanoparticles also exhibit a high r
1 value of 6.99 mM–1 s–1 and a
low r
2 value of 24.11 mM–1 s–1 at a clinically relevant magnetic field (3.0
T). In in vivo experiments, after intravenous administration with
these nanoparticles, the rapid T
2-weighted
effect can be acquired within 5 min and the slow T
1 contrast enhancement at the tumor site appears at 90
min. The explanation of this phenomenon is possibly due to the different
accumulation rates and states of the nanoparticles in different tissues.
In normal liver tissue, the nanoparticles can be quickly phagocytosed
by a reticuloendothelial system and accumulated in the liver. These
accumulated nanoparticles aggregate, improving the T
2-weighted effect and reducing the T
1-weighted effect. However, because of an enhanced permeation
and retention effect, the nanoparticles are delivered into tumor tissue
gradually and dispersedly, which takes a longer time to generate the T
1-weighted effect at the tumor site. In summary,
these Fe3O4 nanoparticles have significant potential
to improve the diagnostic accuracy and sensitivity in MRI.